0
Medical News and Perspectives |

Targeted Therapies Take Aim Against Lung Cancer and Melanoma

Mike Mitka
JAMA. 2010;304(6):624-626. doi:10.1001/jama.2010.1055.
Text Size: A A A
Published online

Extract

Chicago—Targeted therapies for the treatment of certain cancers garnered keen interest during the American Society of Clinical Oncology's (ASCO’s) annual meeting here in June.

Researchers are studying targeted therapies for non–small cell lung cancer (left). Preliminary findings of a targeted therapy that inhibits a tumor-specific protein called anaplastic lymphoma kinase (ALK) showed promise in an expanded phase 1 study in treating patients with ALK-positive non–small cell lung tumors.

(Photo credit: JAMA. 2003;290(24):3199-3206.)

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Researchers are studying targeted therapies for non–small cell lung cancer (left). Preliminary findings of a targeted therapy that inhibits a tumor-specific protein called anaplastic lymphoma kinase (ALK) showed promise in an expanded phase 1 study in treating patients with ALK-positive non–small cell lung tumors.

(Photo credit: JAMA. 2003;290(24):3199-3206.)

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Melanoma

The Rational Clinical Examination
Make the Diagnosis: Melanoma

brightcove.createExperiences();